Know Cancer

forgot password

Gene Polymorphisms and Symptoms in Lung Cancer Patients

18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

Gene Polymorphisms and Symptoms in Lung Cancer Patients

If you agree to take part in this study, upon being admitted for treatment, you will be
asked about your symptoms (how severe they are and to what degree they affect your
day-to-day functioning).

You will be asked to fill out a symptoms questionnaire each time you are at the clinic for
your treatment and for your follow-up visits. The questionnaire will take about 5 to 10
minutes to complete each time.

You may also be contacted at home so that researchers can follow-up on your experience with
symptoms (only if you are not able to come to the clinic for your chemoradiation treatment
or follow-up visits). If you are contacted by phone, the call should last about 5 to 10
minutes each time.

Researchers will also try to collect some of your leftover blood (that was already drawn and
stored for research studies) from a previous lung cancer study (Ecogenetics of Lung Cancer)
that you participated in at M. D. Anderson. Researchers will use your leftover blood sample
to look at certain genes in your blood that may affect your symptoms. If you did not have
blood collected in the previous lung cancer study, you will have a blood sample (one
tablespoon) drawn when you first agree to participate in this study.

This is an investigational study. Up to 320 patients will take part in this study. All will
be enrolled at M. D. Anderson.

Inclusion Criteria:

- Patient has lung cancer and is being treated at M. D. Anderson.

- At least 18 years of age

- Currently living in the United States

- Enrolled in CPN 91-001 (Molecular epidemiology of lung cancer)

- English or Spanish speaking

Exclusion Criteria:

- Patient is unable to understand the intent of the study.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Patient Symptom Severity (MD Anderson Symptom Inventory Questionnaire)

Outcome Time Frame:

Baseline (before), during (every week for 6 weeks), and after chemoradiation therapy (at 6-12 week intervals)

Safety Issue:


Principal Investigator

Cielito C. Reyes-Gibby, DrPH

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

June 2006

Completion Date:

Related Keywords:

  • Lung Cancer
  • Lung Cancer
  • Epidemiology
  • Symptoms
  • Gene Polymorphisms
  • Questionnaire
  • Survey
  • Lung Neoplasms



UT MD Anderson Cancer Center Houston, Texas  77030